Abstract: The invention provides ftsH polypeptides, polynucleotides encoding ftsH polypeptides and related polynucleotides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic methods for detecting Staphylococcus aureus.

Abstract: Processes for preparing N-methyl-L-alanine derivatives and novel intermediates of the process. The derivatives and intermediates are useful for preparing cell-binding agent/maytansinoid complexes.

Abstract: The invention provides ampS polypeptides and DNA (RNA) encoding ampS polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing ampS polypeptides to screen for antibacterial compounds.

Abstract: The invention provides nrdF polynucleotides encoding nrdF polypeptides from Staphylococcus aureus and methods for producing such polypeptides by recombinant techniques. The invention also provides polynucleotides having high identity to the nrdF polynucleotides. Also provided are preferred methods for utilizing these polynucleotides and polypeptides as diagnostic reagents and in diagnostic assays to screen for microbial infections in organisms and materials.

Abstract: The invention provides lacR polypeptides and polynucleotides encoding lacR polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing lacR polypeptides to screen for antibacterial compounds.

Abstract: The invention provides Histidine Kinase polypeptides and polynucleotides encoding Histidine Kinase polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing Histidine Kinase polypeptides to screen for antibacterial compounds.

Abstract: The invention provides ups (undecaprenyl diphosphate synthase) polypeptides and polynucleotides encoding ups (undecaprenyl diphosphate synthase) polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing ups (undecaprenyl diphosphate synthase) polypeptides to screen for antibacterial compounds.

Abstract: The invention provides spo0J1 polypeptides and polynucleotides encoding spo0J1 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing spo0J1 polypeptides to screen for antibacterial compounds.

Abstract: HMTMF81 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HMTMF81 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.

Abstract: The present invention provides an improved adjuvant formulation and a process for producing said adjuvant. The adjuvant comprises an ISCOM structure comprising a saponin, said ISCOM structure being devoid of additional detergent.

Abstract: The invention provides histidine kinase polypeptides and DNA (RNA) encoding histidine kinase polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing histidine kinase polypeptides to screen for antibacterial compounds.

Abstract: A novel vaccine formulation is provided, comprising a hepatitis B component, particularly hepatitis B surface antigen, in combination with aluminum phosphate and 3 de-O-acylated monophosphoryl lipid A.

Abstract: The invention provides fabZ polypeptides and polynucleotides encoding fabZ polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing fabZ polypeptides to screen for antibacterial compounds.

Abstract: A pharmaceutical formulation comprises, in combination with a penem of formula (I): in which: R1 is hydrogen or an organic substituent group; R2 is a fused bicyclic heterocyclic ring system of general formula:  wherein R4 and R5 are independently hydrogen or one or more substituents replacing hydrogen atoms in the ring system shown; m is 2 or 3; p is zero, 1 or 2; and R3 is hydrogen, a salt-forming cation or an ester-forming group; and the symbol ═/═ indicates that the double bond may be in either the E or Z configuration; and a pharmaceutically acceptable carrier; a &bgr;-lactam antibiotic selected from the group consisting of ceftazidime, cefotaxime, amoxycillin, and piperacillin, and pharmaceutically acceptable derivatives thereof.

Abstract: The invention provides ERA polypeptides and DNA (RNA) encoding ERA polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing ERA polypeptide for the protection against infection, particularly bacterial infections.

Abstract: AXOR34 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing AXOR34 polypeptides and polynucleotides in diagnostic assays. Further disclosed are screening assays to identify agonists and antagonists of the interaction between AXOR34 and its ligands, NmU-8, NmU-25, and NmU-23.

Abstract: The invention provides Fibronectin Binding Protein polypeptides and DNA (RNA) encoding Fibronectin Binding Protein polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing Fibronectin Binding Protein polypeptides to screen for antibacterial compounds.

Abstract: The invention provides Phosphatidylglycerophosphate Synthase polypeptides from Staphylococcus aureus (“pgsA polypeptides”). Also provided are methods for utilizing pgsA polypeptides to screen for antibacterial compounds.

Abstract: This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against pathogenic bacteria, especially anaerobic pathogens.

Abstract: Novel combined vaccine compositions preferentially for administration to adolescents are provided, comprising a hepatitis B viral antigen and a herpes simplex viral antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, an HPV antigen, a VZV antigen, an HCMV antigen, a Toxoplasma gondii antigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.